Introduction/Background It was aimed to present clinicopathologic characteristics of 33 cases diagnosed as endometrium cancer in a tertiary referral hospital.
Methodology Medical records of 33 patients diagnosed histopathologically as endometrium cancer between June 2017 and March 2019 were analysed retrospectively. For staging, FIGO 2009 staging system was used. Grade 1 and 2 endometrioid adenocarcinomas were classified as type 1 endometrial carcinomas (EC). Grade 3 endometrioid adenocarcinomas and the endometrial cancers with non-endometrioid histologie were classified as type 2 ECs. One patient diagnosed as undifferentiated endometrial stromal sarcoma had not been classified as either Type 1 or 2 EC.
Results Demographic characteristics were displayed on table 1. The majority of the cases (90,6%) was postmenopausal and diagnosed as endometrioid adenocancer (81.3%).
90.6% of the cases was multiparous and 68.8% of the cases was obese (BMI ≥30 kg/m2).
Pelvic and paraaortic lymph node dissection was performed in 88.5% of the endometrioid adenocancers and 75% of the serous papillary cancers.
There was no statistically significant difference between type1 and 2 ECs regarding the mean age (60.2±6.9 vs 51.8±20.1 years in Type 1 and 2 retrospectively), the rate of obesity, menopausal status and the confinement to the uterus (p<0.05 for all) (table 2).
Conclusion Endometrial cancer is the most common gynecologic cancer in women. Type 1 ECs, which consists of endometrioid histology and lower grade, account for 70–80% of the cases and are usually diagnosed at early stages. Type 2 ECs which develop from atrophic endometrium are diagnosed generally in older women and at later stages. However, in the present study the mean age was similar in both groups of type 1 and 2 ECs. In the current study, though statistically insignificant, the number of of the cases confined to the uterus (15/21, 71.4%) in type 1 ECs were higher compared to the type 2 ECs.
Disclosure Nothing to disclose.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.